Ketamine/sufentanil nasal spray - Cessatech
Alternative Names: CT-001 Cessatech; Sufentanil/ketamine nasal spray - CessatechLatest Information Update: 10 Jun 2025
At a glance
- Originator Cessatech
- Class Amides; Analgesics; Antidepressants; Behavioural disorder therapies; Cyclohexanes; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
- Mechanism of Action NMDA receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Procedural pain
Most Recent Events
- 28 May 2025 Cessatech plans to initiate regulatory submission to the EMA in 2025
- 28 May 2025 Efficacy and adverse event data from phase II/III trial in Pain released by Cessatech
- 09 May 2025 Cessatech completes a phase II/III trial in Procedural pain (In infants, In children, In adolescents) in Spain (Intranasal) (NCT06364072)